Visionsense files for an Inter Partes Review (IPR) against Novadaq's US Patent 8,892,190

PHILADELPHIA, May 16, 2017 /PRNewswire/ -- On May 11, 2017 Visionsense filed an IPR with the USPTO to challenge the Novadaq Technologies's (NVDQ) US Patent 8,892,190.  The '190 patent describes a method for using fluorescence angiography to assess patency of vessel grafts.  The '190 is the only patent specifically identified on the Novadaq website as associated with the SPY Elite system (per Novadaq's website http://novadaq.com/patents/ as of May 15, 2017).   

The use of fluorescence imaging for assessment of vessel grafts is a known technique that dates back to the late 1970s; long before the priority date of the '190 patent.  Articles such as [Little, John R., et al. "Superficial temporal artery to middle cerebral artery anastomosis: intraoperative evaluation by fluorescein angiography and xenon-133 clearance." Journal of neurosurgery 50.5 (1979): 560-569] and third party patents such as [U.S. Patent 6,351,663.  "Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation," filed September 10, 1999], as well as other publications, predate the '190 patent and describe the use of fluorescence imaging to assess vessels.  Visionsense's IPR uses these publications and others to show that claims of the '190 are anticipated and/or obvious over existing prior art.  

Also included in the IPR is a detailed expert analysis of the patent a Chief of Neurosurgery at a well-known US hospital who specializes in vessel grafts.   

Alex Chanin, the president and CEO of Visionsense noted: "our modern fluorescence imaging technology provides significant innovation, economic value and clinical value to surgeons. Filing of this IPR is consistent with our intellectual property strategy for our products." 

For more details, please go to https://ptabtrials.uspto.gov/prweb/PRServlet  and search for IPR2017-01426.

Contact:
Alex Chanin
[email protected]

SOURCE Visionsense Corp.